U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry UNKNOWN
Molecular Formula C6H10N2O3
Molecular Weight 158.1552
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXIRACETAM

SMILES

NC(=O)CN1CC(O)CC1=O

InChI

InChIKey=IHLAQQPQKRMGSS-UHFFFAOYSA-N
InChI=1S/C6H10N2O3/c7-5(10)3-8-2-4(9)1-6(8)11/h4,9H,1-3H2,(H2,7,10)

HIDE SMILES / InChI

Molecular Formula C6H10N2O3
Molecular Weight 158.1552
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1444879 | https://www.ncbi.nlm.nih.gov/pubmed/7586900 | https://www.ncbi.nlm.nih.gov/pubmed/8456595 | https://www.ncbi.nlm.nih.gov/pubmed/3556550

Oxiracetam (ISF 2522) is a water-soluble ampakine of the nootropic racetam chemical class. Oxiracetam is a positive AMPA modulator similar in mechanism and potency (but not the binding site) to both piracetam and aniracetam but may have an additional benefit of increasing glutamate, acetylcholine, and D-aspartic acid release from activated but not resting neurons. Oxiracetam has been proved as an efficient memory enhancer if taken consistently. Additionally, studies have revealed positive impacts on demented patients in the long term. Thus, the drug enhances an overall quality of life of patients suffering from ADHD, dementia, and other neurological problems. Oxiracetam is one of the most popular nootropics, well known and highly regarded for its outstanding cognitive enhancement properties and mild stimulant capability. It has also been proven to be safe and well tolerated even at high dosages, and its moderate cost, ready availability and “stackability” make it a must-have for many nootropic users.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Neuromed

Approved Use

Unknown
Primary
Neuromed

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine.
1987 Jul
Brain entry and direct central pharmacological effects of the nootropic drug oxiracetam. Oxiracetam: brain entry and pharmacological effects.
1989 Oct
Effect of oxiracetam on scopolamine-induced amnesia in the rat in a spatial learning task.
1992 Nov
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
1993 Dec 24
The effects of ascorbic acid and oxiracetam on scopolamine-induced amnesia in a habituation test in aged mice.
1995 Sep
Aniracetam improves contextual fear conditioning and increases hippocampal gamma-PKC activation in DBA/2J mice.
2002
Human models as tools in the development of psychotropic drugs.
2002 Dec
Oxiracetam prevented the scopolamine but not the diazepam induced memory deficits in mice.
2002 Jul 18
Mild cognitive impairment: animal models.
2004 Dec
Rapid quantitative analysis of oxiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry.
2004 Nov 15
Nootropic nefiracetam inhibits proconvulsant action of peripheral-type benzodiazepines in epileptic mutant EL mice.
2004 Oct
Rapid quantitative analysis of oxiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry.
2004 Sep 21
Oxiracetam pre- but not post-treatment prevented social recognition deficits produced with trimethyltin in rats.
2005 Jun 20
[Evaluation of antihypoxic and antiamnemonic effects of mexicor in animals].
2009 Nov-Dec
[Optimization of preparation of poly ( glycidyl methacrylate-divinylbenzene) monolithic column with orthogonal experiments for separation of small molecules].
2010 Feb
Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.
2010 Feb 12
Efficacy study of Prunus amygdalus (almond) nuts in scopolamine-induced amnesia in rats.
2010 Jun
Determination of piracetam in rat plasma by LC-MS/MS and its application to pharmacokinetics.
2010 Oct
Patents

Sample Use Guides

800 mg bid (1600 mg/day)
Route of Administration: Oral
To record currents through Ca2+ channels, a whole cell variation of the patch-clamp technique was applied to NG108-15 cells. Step depolarizations lasting 160 milliseconds were applied to a holding potential of −50 mV to induce high-voltage– activated (HVA) Ca2+ channel currents. Under such experimental conditions, low-voltage–activated (LVA) Ttype Ca2+ channels were practically inactivated at the end of the pulse, allowing us to measure the amplitude of N/L-type Ca2+ channel currents. The external and internal (pipette-filling) solutions were designed to separate Ca2+ channel currents from other ionic currents
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:07:11 GMT 2023
Edited
by admin
on Fri Dec 15 15:07:11 GMT 2023
Record UNII
P7U817352G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXIRACETAM
INN   MART.   MI   WHO-DD  
INN  
Official Name English
OXIRACETAM [JAN]
Common Name English
CGP-21690E
Code English
GNF-PF-1005
Code English
CGP 21690E
Code English
Oxiracetam [WHO-DD]
Common Name English
oxiracetam [INN]
Common Name English
OXIRACETAM [MI]
Common Name English
OXIRACETAM [MART.]
Common Name English
4-HYDROXY-2-OXO-PYRROLIDINACETAMIDE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C1509
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
WHO-VATC QN06BX07
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
DSLD 1891 (Number of products:4)
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
WHO-ATC N06BX07
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
Code System Code Type Description
PUBCHEM
4626
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
PRIMARY
SMS_ID
100000083066
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
PRIMARY
EPA CompTox
DTXSID9045180
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
PRIMARY
DRUG BANK
DB13601
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
PRIMARY
MESH
C040619
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
PRIMARY
DRUG CENTRAL
2021
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
PRIMARY
RXCUI
32645
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
PRIMARY RxNorm
EVMPD
SUB09536MIG
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
PRIMARY
NCI_THESAURUS
C66271
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
PRIMARY
INN
4762
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
PRIMARY
ChEMBL
CHEMBL36633
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
PRIMARY
FDA UNII
P7U817352G
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
PRIMARY
CAS
62613-82-5
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
CONCEPT Dietary Supplement
WIKIPEDIA
OXIRACETAM
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
PRIMARY
MERCK INDEX
m8311
Created by admin on Fri Dec 15 15:07:11 GMT 2023 , Edited by admin on Fri Dec 15 15:07:11 GMT 2023
PRIMARY Merck Index
Related Record Type Details
TARGET->POSITIVE ALLOSTERIC MODULATOR (PAM)
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents
Related Record Type Details
ACTIVE MOIETY